Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
91054 trials found · Page 123 of 4553
-
New hope for lung cancer patients: drug cocktail may prevent Radiation-Induced lung injury
Disease control Not yet recruitingCurrently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) with concurrent chemotherapy, followed by immune checkpoint inhibitors (ICI). RT is a highly effect local treatment. However, high doses of radiatio…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 07, 2026 11:18 UTC
-
New drug combo aims to shrink liver tumors before surgery
Disease control Not yet recruitingThis study aims to investigate the efficacy and safety of neoadjuvant therapy with Iparomlimab and Tuvonralimab Injection (anti-PD-1 and anti-CTLA-4 antibody combination) in patients with resectable hepatocellular carcinoma at high risk of recurrence (Stage IB, Stage IIA).
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New combo approach may extend life for advanced liver cancer patients
Disease control Not yet recruitingThis study evaluates whether comprehensive local consolidative therapy added to continued sintilimab plus lenvatinib improves survival compared with continued sintilimab plus lenvatinib alone in patients with oligo-extrahepatic metastatic hepatocellular carcinoma. All enrolled pa…
Phase: PHASE3 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New hope for advanced breast cancer: experimental drug JSKN003 faces off against standard care
Disease control Not yet recruitingThis study is a randomized, controlled, open-label, multicenter, phase II superiority clinical trial. The planned study population consists of participants with HER2-positive recurrent or metastatic breast cancer who have not previously received systemic therapy for advanced dise…
Phase: PHASE2 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
New combo therapy targets brain lining spread in lung cancer patients
Disease control Not yet recruitingA Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 04, 2026 16:21 UTC
-
Sound waves instead of surgery: new heart valve treatment under study
Disease control Not yet recruitingThe VALvosoft Outcomes Registry for Real-World Evidence (VALOR-PMCF) is a prospective, multicenter, single-arm post-market clinical follow-up (PMCF) registry designed to evaluate the long-term safety and effectiveness of the Valvosoft® non-invasive ultrasound therapy (NIUT) devic…
Sponsor: Cardiawave SA • Aim: Disease control
Last updated May 06, 2026 16:00 UTC
-
New combo therapy aims to tackle Tough-to-Treat blood cancer
Disease control Recruiting nowThis phase II trial studies how well the addition of nemtabrutinib to lisocabtagene maraleucel in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has come back after a period of improvement (relapsed) or that does not respond to treat…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New hope for kids with Crohn's: drug trial targets gut inflammation
Disease control Not yet recruitingThis phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New hope for rare brain disorder: drug trial targets PSP progression
Disease control Not yet recruitingThis Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Immunotherapy duo aims to wipe out hidden colorectal cancer cells
Disease control Not yet recruitingThis phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the blood. Immunotherapy with monoclonal antibodies, suc…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
New drug combo targets tough prostate cancer
Disease control Not yet recruitingThis is a single-institution, single-arm, open-label Phase 2 trial evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs. In those progressing after second-line Docetaxel or deemed ineligible to it, the use of alternate ARSI remains the most common line of th…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 04, 2026 16:21 UTC
-
New drug combo aims for deeper remission in tough blood cancers
Disease control Not yet recruitingThis phase II MyeloMATCH treatment substudy tests the addition of olutasidenib to usual treatment in patients with higher-risk myelodysplastic syndrome (MDS) or patients with acute myeloid leukemia (AML) with a mutation in the IDH1 gene. Olutasidenib blocks the protein made by th…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
New gene therapy injection targets Parkinson's at its genetic root
Disease control Not yet recruitingA Phase I/II Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R08b Intra-cerebroventricular injection in Parkinson's Disease Patients with GBA1 Mutations
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
Toothbrush against transplant disease: dental cleaning may stop GVHD
Prevention Recruiting nowThis clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for som…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated May 04, 2026 16:21 UTC
-
New obesity drug CagriSema takes on semaglutide in massive 2500-person trial
Disease control Not yet recruitingThis clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participan…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
New combo therapy could help rectal cancer patients avoid surgery
Disease control Not yet recruitingThis study is for adults with locally advanced rectal cancer that has not spread to distant organs, and is classified as pMMR or MSS (which means it typically does not respond well to immunotherapy alone). The purpose is to see if a new combination of treatments given before surg…
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated May 05, 2026 11:52 UTC
-
New program aims to curb overdose deaths among women leaving rural jails
Prevention Not yet recruitingThis project continues our work with women in the Kentucky Women's Justice Community Overdose Innovation Network Phase II (WJCOIN-II) with the overall aim of reducing overdose risk during the transition from jail to rural communities. WJCOIN-II has potential for significant impac…
Phase: NA • Sponsor: Michele Staton • Aim: Prevention
Last updated May 06, 2026 16:15 UTC
-
New hope for rare leukemia: drug duo enters human testing
Disease control Not yet recruitingTo learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 2 trial
Disease control Recruiting nowTo find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:29 UTC
-
New hope for stage 4 lung cancer? experimental combo enters late-stage trial
Disease control Not yet recruitingThis is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Phase: PHASE2, PHASE3 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:30 UTC